Engineered herpes virus that delivers an anti‑CD47 antibody to target glioblastoma
An engineered oncolytic herpes virus expressing a full-length α-CD47 mAb for the treatment of GBM
['FUNDING_OTHER'] · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · NIH-11184279
This project uses a modified herpes virus that makes an anti‑CD47 antibody at the tumor to help the immune system attack glioblastoma in adults.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE (nih funded) |
| Locations | 1 site (DUARTE, UNITED STATES) |
| Trial ID | NIH-11184279 on ClinicalTrials.gov |
What this research studies
Researchers engineered an oncolytic herpes simplex virus to produce a full‑length anti‑CD47 antibody directly at brain tumor sites. The antibody aims to block the tumor’s “don’t eat me” signal and recruit immune cells (macrophages and natural killer cells) to kill glioblastoma cells through phagocytosis and cytotoxicity. The team has shown improved survival in mouse models and is developing this approach toward safe use in the brain. The work is currently preclinical but is being advanced with the goal of eventual clinical testing for adult GBM patients.
Who could benefit from this research
Good fit: Adults (21+) with glioblastoma could be candidates for future clinical trials of this therapy, especially those whose tumors are suitable for local delivery.
Not a fit: People without glioblastoma, children, or patients whose tumors cannot be reached safely by local virus delivery or who have unstable medical conditions are unlikely to benefit from this work.
Why it matters
Potential benefit: If successful, this approach could boost the immune system’s ability to clear glioblastoma cells and potentially improve survival with reduced systemic side effects.
How similar studies have performed: Oncolytic viruses and anti‑CD47 therapies have shown promise separately in preclinical and some clinical settings, but using an oHSV to produce a full‑length anti‑CD47 antibody in the brain is a novel approach so far demonstrated mainly in animal models.
Where this research is happening
DUARTE, UNITED STATES
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE — DUARTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BADIE, BEHNAM — BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- Study coordinator: BADIE, BEHNAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.